Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?
Venkat Reddy(University College London), Maria Leandro(University College Hospital), Loren Kell(Center for Rheumatology), David Isenberg(Regenerative Medicine Institute), Christian Klein(Roche (Switzerland)), Geraldine Cambridge(University College London), Mark S. Cragg(University of Southampton), Scott R Henderson(The Royal Free Hospital), Samuel J. Taylor(University of Western Australia), Ruth J. Pepper(University College Hospital), Kavina Shah(University College London Hospitals NHS Foundation Trust)
Cited by 38
Related Papers
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
|The Lancet Haematology|2016|404
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355